

Approved by the AUA Board of Directors April 2014

Authors' disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article.

© 2014 by the American Urological Association

#### Note to the Reader:

On July 26, 2013, the FDA issued a safety announcement related to the use of ketoconazole in the form of oral tablets. Side effects can include hepatotoxicity, adrenal insufficiency and dangerous drug interactions.

This document was amended in April 2014 to reflect literature that was released since the original publication of this guideline in May 2013.

This document will be periodically updated to reflect the growing body of literature related to this disease.

## American Urological Association (AUA) Guideline

### CASTRATION-RESISTANT PROSTATE CANCER: AUA GUIDELINE

**Michael S. Cookson, Bruce J. Roth, Philipp Dahm, Christine Engstrom, Stephen J. Freedland, Maha Hussain, Daniel W. Lin, William T. Lowrance, Mohammad Hassan Murad, William K. Oh, David F. Penson and Adam S. Kibel**

**Purpose:** As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with metastatic castration-resistant prostate cancer (CRPC), clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. To assist in clinical decision-making, six index patients were developed representing the most common clinical scenarios that are encountered in clinical practice. With these patients in mind, guideline statements were developed to provide a rational basis for treatment based on currently available published data.

**Methodology:** A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The search strategy was developed and executed by reference librarians and methodologists to create a final evidence report limited to English-language, peer-reviewed literature published between January 1996 and February 2013. This review yielded 303 articles, which were used to inform the statements presented in the guideline as Standards, Recommendations or Options. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low). In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions.

#### Guideline Statements

##### Index Patient 1

1. Clinicians should recommend observation with continued androgen deprivation to patients with non-metastatic CRPC. (Recommendation; Evidence Level Grade C)
2. Clinicians may offer treatment with first-generation anti-androgens (flutamide, bicalutamide and nilutamide) or first generation androgen synthesis inhibitors (ketoconazole+steroid) to select patients with non-metastatic CRPC who are unwilling to accept observation. (Option; Evidence Level Grade C)
3. Clinicians should not offer systemic chemotherapy or immunotherapy to patients with non-metastatic CRPC outside the context of a clinical trial. (Recommendation; Evidence Level Grade C)

##### Index Patient 2

4. Clinicians should offer abiraterone + prednisone, docetaxel, or sipuleucel-T to patients with asymptomatic or minimally symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy. [Standard; Evidence Level Grade A (abiraterone)/B (docetaxel) /B (sipuleucel-T)]
5. Clinicians may offer first-generation anti-androgen therapy, ketoconazole + steroid or observation to patients with asymptomatic or minimally symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy who do not want or cannot have one of the standard therapies. (Option; Evidence Level Grade C)

**Index Patient 3**

6. Clinicians should offer docetaxel to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy. (Standard; Evidence Level Grade B)
7. Clinicians may offer abiraterone + prednisone to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy. (Recommendation; Evidence Level Grade C)
8. Clinicians may offer ketoconazole + steroid, mitoxantrone or radionuclide therapy to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy who do not want or cannot have one of the standard therapies. [Option; Evidence Level Grade C (ketoconazole) /B (mitoxantrone) / C (radionuclide therapy)]
9. Clinicians should offer radium-223 to patients with symptoms from bony metastases from mCRPC with good performance status and no prior docetaxel chemotherapy and without known visceral disease. (Standard; Evidence Level Grade B)
10. Clinicians should not offer treatment with either estramustine or sipuleucel-T to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy. (Recommendation; Evidence Level Grade C)

**Index Patient 4**

11. Clinicians may offer treatment with abiraterone + prednisone to patients with symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy. (Option; Evidence Level Grade C)
12. Clinicians may offer treatment with ketoconazole+ steroid or radionuclide therapy to patients with symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy who are unable or unwilling to receive abiraterone + prednisone. (Option; Evidence Level Grade C)
13. Clinicians may offer docetaxel or mitoxantrone chemotherapy to patients with symptomatic mCRPC with poor performance status and no prior docetaxel chemotherapy in select cases, specifically when the performance status is directly related to the cancer. (Expert Opinion)
14. Clinicians may offer radium-223 to patients with symptoms from bony metastases from mCRPC with poor performance status and no prior docetaxel chemotherapy and without known visceral disease in select cases, specifically when the performance status is directly related to symptoms related to bone metastases. (Expert Opinion)
15. Clinicians should not offer sipuleucel-T to patients with symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy. (Recommendation; Evidence Level Grade C)

**Index Patient 5**

16. Clinicians should offer treatment with abiraterone + prednisone, cabazitaxel or enzalutamide to patients with mCRPC with good performance status who received prior docetaxel chemotherapy. If the patient received abiraterone + prednisone prior to docetaxel chemotherapy, they should be offered cabazitaxel or enzalutamide. [Standard; Evidence Level Grade A (abiraterone) / B (cabazitaxel)/ A (enzalutamide)]
17. Clinicians may offer ketoconazole + steroid to patients with mCRPC with good performance status who received prior docetaxel if abiraterone + prednisone, cabazitaxel or enzalutamide is unavailable. (Option; Evidence Level Grade C)
18. Clinicians may offer retreatment with docetaxel to patients with mCRPC with good performance status who were benefitting at the time of discontinuation (due to reversible side effects) of docetaxel chemotherapy. (Option; Evidence Level Grade C)
19. Clinicians should offer radium-223 to patients with symptoms from bony metastases from mCRPC with good performance status who received prior docetaxel chemotherapy and without known visceral disease. (Standard; Evidence Level Grade B)

**Index Patient 6**

20. Clinicians should offer palliative care to patients with mCRPC with poor performance status who received prior docetaxel chemotherapy. Alternatively, for selected patients, clinicians may offer treatment with abiraterone + prednisone, enzalutamide, ketoconazole + steroid or radionuclide therapy. (Expert Opinion)

- 21.** Clinicians should not offer systemic chemotherapy or immunotherapy to patients with mCRPC with poor performance status who received prior docetaxel chemotherapy. (Expert Opinion)

**Bone Health**

- 22.** Clinicians should offer preventative treatment (e.g. supplemental calcium, vitamin D) for fractures and skeletal related events to CRPC patients. (Recommendation; Evidence Level Grade C)
- 23.** Clinicians may choose either denosumab or zoledronic acid when selecting a preventative treatment for skeletal related events for mCRPC patients with bony metastases. (Option; Evidence Level Grade C)

## Introduction

**Incidence and Epidemiology.** Prostate cancer is the most commonly diagnosed solid organ malignancy in the United States (US) and remains the second leading cause of cancer deaths among American men. Approximately 240,000 new diagnoses of prostate cancer and over 28,000 deaths were estimated in the US in 2012.<sup>1</sup> Prostate cancer deaths are typically the result of metastatic castration-resistant prostate cancer (mCRPC), and historically the median survival for men with mCRPC has been less than two years. The recent availability of novel treatments for mCRPC has given a resurgence of hope for these men as studies now demonstrate improved survival with a variety of new agents. However, the unfortunate reality is that mCRPC remains an incurable disease, and it is against this backdrop that we look to the future with cautious optimism and new hope for scientific discovery.

The exact mechanism of transition from castration-sensitive prostate cancer to castration-resistant disease is still not fully understood, but with recent scientific breakthroughs in basic research, there is now a greater understanding. We now know that despite castrate levels of androgens, the androgen receptor (AR) remains active and continues to drive prostate cancer progression.<sup>2,3</sup> This understanding has led to the development of novel agents aimed at further decreasing androgen production or blocking AR function. However, there are also many other biologic pathways that function independent of androgen signaling resulting in CRPC. With a greater understanding of the tumor biology, there is hope for continued development of innovative treatment options that improve survival for men with mCRPC.

The treatment of men with mCRPC has dramatically changed over the past decade. Prior to 2004, once patients failed primary androgen deprivation, treatments were administered solely for palliation. Landmark articles by Tannock et al.<sup>4</sup> and Petrylak et al.<sup>5</sup> demonstrated that docetaxel improved survival for these patients with mCRPC. Since the approval of docetaxel, five additional agents that show a survival benefit have been FDA-approved on the basis of randomized clinical trials. These have included enzalutamide and abiraterone, two agents designed specifically to affect the androgen axis;<sup>6,7</sup> sipuleucel-T, which stimulates the immune system;<sup>8</sup> cabazitaxel, a chemotherapeutic agent;<sup>9</sup> and radium-223, a radionuclide therapy.<sup>10</sup> These agents have been tested in multiple “disease states” of CRPC to determine if or when patients might benefit from each treatment. Other treatments for men with mCRPC have been shown to improve outcomes, but remain to be approved by the FDA.<sup>11</sup>

**Guideline Purpose.** As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with mCRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. These Guidelines were developed to provide a rational basis for treatment of patients with CRPC, based on currently available published data. To assist in clinical decision-making, six index patients were developed representing the most common clinical scenarios that are encountered in clinical practice. These index patients were created based on the presence or absence of metastatic disease, the degree of symptoms, the patients’ performance status (as defined by the ECOG scale) and the prior treatment with docetaxel-based chemotherapy.

1. Asymptomatic non-metastatic CRPC
2. Asymptomatic or minimally-symptomatic, mCRPC without prior docetaxel chemotherapy
3. Symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy
4. Symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy
5. Symptomatic, mCRPC with good performance status and prior docetaxel chemotherapy
6. Symptomatic, mCRPC with poor performance status and prior docetaxel chemotherapy

Once index patients were developed, the literature was reviewed using the protocol described in the methodology section of this document.

The goal of this Guideline is to provide evidence based recommendations for the treatment of CRPC. Since this is a rapidly evolving field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient’s treatment goals. In all cases, the patient’s preferences and personal goals should be considered when choosing therapy. Although we are discussing castration-resistant disease, we support the standard of care to maintain castrate testosterone levels even in the face of castration-resistant disease. A flowchart summarizing the guideline statements of this document can be found in Appendix B.

## Methodology

**Process for Initial Literature Selection.** Consistent with the AUA published guideline methodology framework,<sup>12</sup> the process started by conducting a comprehensive systematic review. The AUA

<sup>1</sup>Please see Appendix A for the ECOG Performance Status Table

commissioned an independent group to conduct a systematic review and meta-analysis of the published literature on various therapies for CRPC. The protocol of the systematic review was developed *a priori* by the methodology team in conjunction with the expert panel. The search strategy was developed and executed by reference librarians and methodologists and spanned across multiple databases including Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, Ovid Cochrane Central Register of Controlled Trials and Scopus. The evidence report was limited to English-language, peer-reviewed literature published between January 1996 and February 2013. Controlled vocabulary supplemented with keywords was used to search for the relevant concepts of prostate cancer and castration resistance (biochemical recurrence with a rising PSA and/or progression of disease by radiographic criteria despite a castrate testosterone level). An expert panel manually identified additional references to supplement the electronic search, which were required to meet the same criteria as the previously used studies.

The search strategy focused on commonly used as well as experimental therapies including systemic chemotherapy (estrामustine, mitoxantrone, docetaxel, cabazitaxel), immunotherapy (sipuleucel-T) and vaccine therapy, agents targeting the androgen signaling pathway (abiraterone, ketoconazole, corticosteroids, antiandrogens), radiotherapy and radiopharmaceuticals (Strontium-89 [Metastron®], Samarium-153 [Quadramet®]), antiandrogen withdrawal, bone targeted therapies (zoledronic acid, denosumab), enzalutamide [androgen receptor inhibitor], palliative care and experimental therapy, (TAK700 [CYP-17 inhibitor], cabozantinib [cMET/VEGFR inhibitor], Radium-223 [Alpharadin®]).

The outcomes of interest were *a priori* determined by the panel based on their respective importance to patients, recognizing that some of these endpoints are surrogates for the patients and included overall survival (OS), progression-free survival (PFS), metastasis-free survival, PSA PFS, PSA decline, measurable disease response, adverse events/side-effects of treatment, quality of life (QOL), skeletal-related events (SREs), pain-free survival, and pain response.

The methodology team independently rated the methodological quality of the studies and provided an overall judgment of the whole body of evidence based on confidence in the available estimates of effect.

The methodology team summarized the data with explicit description of study characteristics, methodological quality, main findings and the quality of the evidence (confidence in the estimates). The

methodology team attended panel meetings and facilitated incorporation of the evidence into the guideline.

**Quality of Individual Studies and Determination of Evidence Strength.** The systematic review included 303 eligible studies that addressed the pre-identified questions of interest. A large body of evidence evaluated established chemotherapy agents such as docetaxel [19 Randomized controlled trials (RCTs)], estramustine (5 RCTs) and mitoxantrone (5 RCTs). Randomized evidence was also available for various immunotherapies (8 RCTs), therapies targeting the androgen signaling pathway (12 RCTs), radiotherapy and radiopharmaceuticals (4 RCTs) and bone-targeting therapies (6 RCTs). The quality of these trials was acceptable overall and ranged from moderate to low risk of bias. All the remaining studies were otherwise non-randomized (observational) and considered to be at high risk of bias.

The quality of the evidence (confidence in the estimates) was limited in many studies by indirectness. Indirectness occurs when studies use surrogate endpoints that depend on laboratory or radiographic measurements (PSA free survival, PSA decline or PFS based on imaging).<sup>13</sup> These outcomes usually are surrogates for other important patient outcomes more essential for decision making, such as mortality, pain and QOL. Imprecision (wide confidence intervals due to small number of events) was also common in most CRPC trials and can lower the confidence in the provided estimates.

**Limitations of the Literature.** The systematic review and guideline process identified clear gaps in the available evidence base. None of the therapies identified in this review were curative or resulted in long term remission. Therefore, primary research on new agents is clearly needed for this important and common condition. Future trials should also use and incorporate patient reported outcomes, such as QOL and pain control. The current evidence base suffers from imprecision that can be overcome by multi-site RCT collaboration or prospective (pre-planned) meta-analyses.

**Guideline Amendment.** In April 2014, the CRPC guideline underwent the amendment process to incorporate additional literature released since the initial publication of this guideline. A comprehensive search of several databases from February 2013 to February 2014, English language, was conducted. The databases included Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, Ovid Cochrane Central Register of Controlled Trials, and Scopus. The search strategy was designed and

conducted by an experienced librarian with input from the study's principle investigator. Controlled vocabulary supplemented with keywords was used to search for studies on therapy for castration resistant prostate cancer.

The search yielded 998 references, of which 662 were excluded after duplicate abstract and title review. We retrieved the full texts for the 336 included studies. Eventually, 37 studies provided relevant data on the specific treatment modalities for CRPC.

**AUA Nomenclature: Linking Statement Type to Evidence Strength.** The AUA nomenclature system explicitly links statement type to body of evidence strength and the Panel's judgment regarding the balance between benefits and risks/burdens (see Table 1).<sup>12</sup> The framework of rating the quality of evidence is an adaptation and modification<sup>12</sup> of the GRADE framework (Grading of Recommendations, Assessment, Development and Evaluation).<sup>13,14</sup> In this adaptation, the AUA rates the quality of evidence as high, moderate or low (A, B or C). **Standards** are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken based on Grade A or Grade B evidence. **Recommendations** are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken based on Grade C evidence. **Options** are non-directive statements that leave the decision to take an action up to the individual clinician and patient because the balance between benefits and risks/burdens appears relatively equal or appears unclear; **Options** may be supported by Grade A, B or C evidence. It is important to note that grading (A, B or C) does not reflect the magnitude of a potential benefit or harm, but is instead related to the methodological review of the study. For some clinical issues, there was little or no evidence from which to construct evidence-based statements. Where gaps in the evidence existed, the Panel provides guidance in the form of **Clinical Principles** or **Expert Opinions** with consensus achieved using a modified Delphi technique if differences of opinion existed among Panel members.<sup>15</sup> A **Clinical Principle** is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. **Expert Opinion** refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge and judgment and for which there is no evidence. The completed evidence report may be requested through AUA.

**Panel Selection and Peer Review Process.** The Panel was created by the American Urological Association Education and Research, Inc. (AUA). The

**Table 1: AUA Nomenclature Linking Statement Type to Evidence Strength**

<b>Standard:</b> Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on Grade A or B evidence
<b>Recommendation:</b> Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on Grade C evidence
<b>Option:</b> Non-directive statement that leaves the decision regarding an action up to the individual clinician and patient because the balance between benefits and risks/burdens appears equal or appears uncertain based on Grade A, B, or C evidence
<b>Clinical Principle:</b> a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature
<b>Expert Opinion:</b> a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and

Practice Guidelines Committee (PGC) of the AUA selected the Panel Chair and Vice Chair who in turn appointed the additional panel members, all of whom have specific expertise with regard to the guideline subject to include both urologists and medical oncologists.

Once nominated, panel members are asked to record their conflict of interest (COI) statements, providing specific details on the AUA interactive web site. These details are first reviewed by the Guidelines Oversight Committee (GOC), a member sub-committee from the PGC consisting of the Vice Chair of the PGC and two other members. The GOC determines whether the individual has potential conflicts related to the guideline. If there are no conflicts, then the nominee's COI is reviewed and approved by the AUA Judicial and Ethics (J&E) committee. A majority of panel members may not have relationships relevant to the guideline topic.

The AUA conducted an extensive peer review process. The initial draft of this Guideline was distributed to 56 peer reviewers of varying backgrounds; 30 responded with comments. The panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the Guideline was submitted for approval to the PGC. It was then submitted to the AUA Board of Directors for final approval. Funding of the panel was provided by the AUA. Panel members

received no remuneration for their work.

### **Index Patient 1**

Asymptomatic non-metastatic CRPC

One of the first clinical presentations of CRPC occurs in a patient with a rising PSA despite medical or surgical castration. This is typically defined as a patient with a rising PSA and no radiologic evidence of metastatic prostate cancer. The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) defines PSA only failure as a rising PSA that is greater than 2ng/mL higher than the nadir; the rise has to be at least 25% over nadir and the rise has to be confirmed by a second PSA at least three weeks later. In addition, the patient is required to have castrate levels of testosterone (less than 50 ng/mL) and no radiographic evidence of metastatic disease.<sup>16</sup> These patients represent a relatively common clinical presentation and the earliest clinical manifestation of castration resistance, but to date, there are no randomized trials showing an OS benefit in this patient population from a particular form of treatment.

#### **Guideline Statement 1.**

***Clinicians should recommend observation with continued androgen deprivation to patients with non-metastatic CRPC. (Recommendation; Evidence Level Grade C)***

**Discussion:** In men with non-metastatic CRPC, no treatment has been shown to prolong OS. Since all agents have potential side effects and no treatment has been shown to extend survival, we must first do no harm. As such, it is the panel judgment that no treatment (i.e. observation) other than continued androgen deprivation therapy (ADT) be the recommended treatment based upon the lack of any data to refute this recommendation. Given the lack of data showing that any treatment in this disease setting meaningfully impacts clinical outcome, there is a strong panel judgment that patients should be encouraged to enter clinical trials, when available.

#### **Guideline Statement 2.**

***Clinicians may offer treatment with first-generation anti-androgens (flutamide, bicalutamide and nilutamide) or first generation androgen synthesis inhibitors (ketoconazole+steroid) to select patients with non-metastatic CRPC who are unwilling to accept observation. (Option; Evidence Level Grade C)***

**Discussion:** While it is the panel's judgment that observation is the most appropriate treatment for this patient population, some patients in this setting may be

uncomfortable with treatment with systematic ADT alone and may wish to initiate additional treatment despite the lack of good evidence with regards to their benefits and harms in this setting.

**Anti-androgens:** Though anti-androgens (flutamide, bicalutamide and nilutamide) are commonly used, these agents can be associated with side effects including gastrointestinal upset and liver toxicity. Though some small single-arm non-randomized studies suggest a PSA benefit,<sup>17-22</sup> the actual PSA benefit appears modest with PSA declines >50% occurring typically in 20-40% of men with a median duration measured in several months. In addition, anti-androgen withdrawal has been used as an option in this setting. There are no randomized studies of either anti-androgens or anti-androgen withdrawal compared to observation, and as such there is a lack of data suggesting any meaningful clinical benefit, such as delayed disease progression, improved QOL or OS compared to the recommended treatment of observation. As such, the data associated with this statement rated a C-level. There are no published reports of the newest generation of oral anti-androgens in this patient population. Though the mechanism of action appears similar to previously-studied anti-androgens, given the lack of data, the efficacy and side effect profile of this newer generation of anti-androgens in this population is unknown.

**Androgen synthesis inhibitors (ketoconazole):** The oral androgen synthesis inhibitor ketoconazole is often used for men with non-metastatic CRPC. Ketoconazole is a weak inhibitor of CYP11A and CYP17A and suppresses the synthesis of adrenal and tumor tissue androgens. Ketoconazole can be associated with nausea and hepatotoxicity and must be given with replacement steroids. There are numerous single-arm studies<sup>23-29</sup> that show PSA response rates (>50% decline in PSA) of 30-60% with typical responses around 50%. Only one published report<sup>30</sup> of abiraterone + prednisone included men with non-metastatic CRPC. Since only four men with non-metastatic CRPC were included in this study, it prevents any meaningful conclusions for the use of such a treatment in this patient population. Additional androgen synthesis inhibitors are available or in development, but there is currently no data to support their use in this patient population.

#### **Guideline Statement 3.**

***Clinicians should not offer systemic chemotherapy or immunotherapy to patients with non-metastatic CRPC outside the context of a clinical trial. (Recommendation; Evidence Level Grade C)***

**Discussion:** The past few years have seen a plethora of new treatments for men with mCRPC. Indeed, multiple agents have been shown to prolong survival

for men with mCRPC. However, there is no data to support their use in this non-metastatic CRPC patient population. Thus, the panel strongly recommends against this practice due to a lack of outcome data in the non-metastatic disease setting.

Of the classes of agents recommended against, only denosumab has been systematically studied in this non-metastatic state. Denosumab 120 mg subcutaneously monthly, which in a placebo-controlled randomized trial,<sup>11</sup> was shown to modestly delay the development of radiographically detected bone metastases, but it did not impact QOL or OS. This agent showed only a modest delay in bone metastases of three months and was specifically denied approval by the FDA for this indication. It was associated with significant side-effects, including osteonecrosis of the jaw. Thus, monthly denosumab is not indicated for non-metastatic CRPC.

Thus, the primary reason the panel recommends against the routine use of these agents in this patient population is concerns about toxicity. All of the agents not recommended have the potential for significant toxicity. While this toxicity may be greater for some classes (i.e. chemotherapy) than others, all of these agents have the potential to harm patients. Thus, the combination of no known benefit with known and potentially serious harms results in a recommendation not to use these agents.

### **Index Patient 2**

Asymptomatic or minimally symptomatic, mCRPC without prior docetaxel chemotherapy

This patient represents a common clinical presentation seen in the CRPC setting today. These patients are characterized as having a rising PSA in the setting of castrate levels of testosterone, documented metastatic disease on radiographic imaging and no prior treatment with docetaxel chemotherapy for CRPC. The key distinction between this patient and Index Patients 3 and 4 is symptom status. Specifically, this patient is defined as having no symptoms or mild symptoms attributable to his prostate cancer. However, one must then consider whether the patient requires regular opioid pain medications for symptoms thought to be attributable to documented metastases to achieve this level of pain control. In general, if patients require regular narcotic medications for pain relief, they are not included in this category. Acknowledging these important definitions, the panel makes the following guidelines statements:

#### ***Guideline statement 4.***

***Clinicians should offer abiraterone + prednisone, docetaxel, or sipuleucel-T to patients with***

***asymptomatic or minimally symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy. [Standard; Evidence Level Grade A (abiraterone)/B (docetaxel) /B (sipuleucel-T)]***

**Discussion:** Abiraterone + prednisone, docetaxel chemotherapy and sipuleucel-T immunotherapy are currently the only agents that have an FDA indication for use in men with mCRPC who have not yet received docetaxel chemotherapy. For each agent, there is a randomized clinical trial that shows a survival benefit for the drug.

**Abiraterone:** Abiraterone is an irreversible inhibitor of the hydroxylase and lyase activities of CYP17A, which catalyzes the conversion of C21 progesterone precursors to C19 adrenal androgens, DHEA and androstenedione. Prior to docetaxel chemotherapy, abiraterone + prednisone has demonstrated an improvement in radiographic PFS and OS. In the COU-AA-302 study, Ryan et al.<sup>31</sup> randomized 1,088 men with mCRPC who had not received prior chemotherapy to receive either abiraterone 1,000mg daily plus prednisone 5mg twice a day or placebo plus prednisone 5 mg twice daily. The primary outcomes of the study were radiographic-progression free and OS. Participants randomized to receive abiraterone + prednisone had statistically significant improvement in radiographic progression-free and OS (HR=0.53 (p<0.001) and 0.75 (p=0.01), respectively). Although grade 3-4 mineralocorticoid related adverse events and liver function abnormalities were more common in the abiraterone group, the agent was generally well-tolerated. Abiraterone is associated with expected increases in mineralocorticoids upstream of CYP17A, accounting for the treatment-related side effects, such as hypertension, hypokalemia, edema and fatigue that respond to low dose glucocorticoids. Use of abiraterone in combination with low-dose prednisone is required to prevent these treatment-related increases in ACTH and attendant side effects.

**Docetaxel:** Docetaxel is a potent inhibitor of microtubule assembly and disassembly. In the TAX-327 trial, Tannock et al.<sup>4</sup> randomized 1,006 men with mCRPC and good performance status to receive 5mg prednisone twice daily and either docetaxel 75mg/M<sup>2</sup> every three weeks; docetaxel 30mg/M<sup>2</sup> weekly or; mitoxantrone 12mg/M<sup>2</sup> weekly. As the primary outcome of this trial was survival, mitoxantrone effectively served as a "placebo" arm, as a prior RCT showed symptom improvement but failed to show a survival advantage associated with mitoxantrone when compared to placebo.<sup>32</sup> Patients who received docetaxel + prednisone every three weeks in TAX-327 had significantly better survival than those receiving mitoxantrone (HR for death: 0.75, p=0.009). Median

survival in the docetaxel + prednisone every three weeks group was 18.9 months compared to 16.5 months in the mitoxantrone group. No significant survival differences were noted between the weekly docetaxel + prednisone group and the mitoxantrone group. While this study provides strong evidence to support the use of docetaxel + prednisone in men with mCRPC, there are two important caveats to bear in mind, particularly when comparing it to later studies on newer agents. First, this study did include many patients with symptomatic mCRPC (Index Patient 3). Second, 26% of patients in the docetaxel + prednisone every three weeks arm had one or more serious adverse events, and roughly 11% of patients in this group discontinued treatment due to adverse events. In a second study, SWOG 9916 tested docetaxel and estramustine v. mitoxantrone and prednisone for 12 cycles in 674 men with mCRPC.<sup>5</sup> Patients in the docetaxel + prednisone arm had improvements in median survival (17.5 v. 15.6 months,  $p=0.02$ ) and time to progression (TTP) (6.3 v. 3.2 months,  $p < 0.001$ ) and a 20% reduction in risk of death. The side effect profile associated with docetaxel may lead patients to delay docetaxel treatment until symptomatic or to elect not to receive this treatment at all. A thorough discussion of the risks and benefits of this treatment is warranted with all patients who are considering this therapy.

**Sipuleucel-T:** Sipuleucel-T is an approved immunotherapy for the management of mCRPC. Sipuleucel-T immunotherapy is an FDA-approved agent in this setting based upon the results of the IMPACT trial, published in 2010.<sup>8</sup> In this randomized double-blind placebo controlled clinical trial, 512 men with asymptomatic or minimally-symptomatic mCRPC and good functional status were randomized to receive either sipuleucel-T or placebo on a 2:1 basis. Compared to placebo, sipuleucel-T was associated with a relative reduction of 22% in the risk of death ( $HR=0.78$ ,  $p=0.03$ ). Median survival in the sipuleucel-T arm was 25.8 months compared to 21.7 months in the placebo arm. It is worth noting that patients receiving sipuleucel-T therapy rarely (<10%) exhibit a clinical, serologic or radiographic response, and, as such, should be counseled appropriately not to expect to see a decline in PSA or reduction in radiologic volume of disease when undergoing this treatment.

In summary, abiraterone + prednisone, docetaxel and sipuleucel-T are considered standard therapies in this index patient. Unfortunately, there are no direct studies comparing the agents that can be used to inform optimal sequencing. As a general principle, it is preferable to give the least toxic agent first, particularly given the lack of head-to-head data, but this must be deliberated in light of other considerations, including convenience of administration. As such, patients

should be informed of all options and be allowed to make an informed decision based upon their own preferences and goals related to therapy.

#### **Guideline Statement 5.**

***Clinicians may offer first-generation anti-androgen therapy, ketoconazole + steroid or observation to patients with asymptomatic or minimally symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy who do not want or cannot have one of the standard therapies. (Option; Evidence Level Grade C)***

**Discussion:** Manipulation with existing anti-androgen agents, such as bicalutamide, nilutamide or flutamide, can only be considered an option in this setting, if only because they offer patients who do not want or cannot have one of the standard therapies a relatively less toxic therapeutic option.

In patients who elect not to receive the standard therapies, there are a number of other options available. Data to support the use of these options in the setting of asymptomatic or minimally-symptomatic prostate cancer is limited and generally of lesser strength than the standard treatments. Some have suggested that the removal of anti-androgen therapy may have a beneficial effect on mCRPC. The majority of these studies supporting this approach are observational.<sup>33-35</sup> The single RCT addressing this issue failed to show any survival benefit associated with anti-androgen withdrawal.<sup>36</sup>

Finally, some patients may not wish to pursue any therapy, waiting for the onset of symptoms to pursue treatment (if they were to ever elect treatment at all). Given current data in this patient population, this approach is a reasonable option. In all cases, the patient's preferences and personal goals should be considered when choosing therapy for asymptomatic or minimally symptomatic CRPC.

#### **Index Patient 3**

Symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy

These patients have a rising PSA in the setting of castrate levels of testosterone, documented symptomatic metastatic disease on radiographic imaging and no prior history of docetaxel chemotherapy for prostate cancer. The definition of symptomatic disease warrants additional explanation to contrast with Index Patient 2. First, the patient must have symptoms that are clearly attributable to the metastatic disease burden, not any other medical condition. Second, if having pain, the patient should require regular opiate

pain medications for symptoms attributable to documented metastases in order to achieve an acceptable level of pain control. If patients require regular narcotic medications for pain relief, then they are symptomatic from their prostate cancer and should be included in this category.

#### **Guideline Statement 6.**

**Clinicians should offer docetaxel to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy. (Standard; Evidence Level Grade B)**

**Discussion:** *Docetaxel:* As previously noted, the TAX-327 and SWOG-9916 studies support the use of first-line docetaxel every three weeks with daily prednisone in symptomatic mCRPC.<sup>4,5</sup> Bone pain responses were more significant in docetaxel patients (35% v. 22%,  $p=0.08$ ), as were improvements in QOL compared to the mitoxantrone group. Updated results showed a similar median survival benefit for docetaxel every three weeks v. mitoxantrone, with three-year survival rates of 18.6% and 13.5%, respectively ( $p=0.005$ ).<sup>37</sup> The magnitude of benefit associated with docetaxel + prednisone treatment for CRPC was independent of age, performance status or baseline PSA.

#### **Guideline Statement 7.**

**Clinicians may offer abiraterone +prednisone to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy. (Recommendation; Evidence Level Grade C)**

**Discussion:** *Abiraterone + prednisone:* In the previously discussed COU-AA-302 study, the Independent Data Monitoring Committee (IDMC) unanimously recommended unblinding based on a planned interim analysis of PFS, OS and clinical benefit. At 22 months of follow up, neither median PFS nor OS for the abiraterone arm had been reached, but the hazard ratio for PFS was reported as 0.53 (95% CI: 0.45, 0.62) and for OS was 0.75 (95% CI: 0.61, 0.93) in favor of abiraterone.<sup>31</sup> While the randomized phase-III trial was only conducted in asymptomatic and minimally symptomatic men, the mechanism of action of abiraterone is similar to that of ketoconazole and has shown marked palliative and skeletal related benefits. Abiraterone is FDA approved for treatment of a symptomatic patient population, and the label specifies only that it is for the treatment of mCRPC; therefore, it is appropriate for Index Patient 3.

#### **Guideline Statement 8.**

**Clinicians may offer ketoconazole + steroid, mitoxantrone or radionuclide therapy to patients**

**with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy who do not want or cannot have one of the standard therapies. [Option; Evidence Level Grade C (ketoconazole) /B (mitoxantrone) / C (radionuclide therapy)]**

**Discussion:** *Ketoconazole:* Ketoconazole has not shown significant OS improvements in patients with symptomatic, chemotherapy-naive mCRPC. Ketoconazole has substantial treatment-related side effects that have prompted the development of more potent CYP17A inhibitors, such as abiraterone. The side effects of ketoconazole and management and administration considerations are addressed in Index Patient 1.

*Mitoxantrone:* Mitoxantrone, a microtubule inhibitor, has not shown a survival benefit compared to docetaxel-based chemotherapy regimens in mCRPC, as previously discussed.<sup>4</sup> Mitoxantrone is primarily utilized in symptomatic mCRPC patients with poor performance status (i.e. not candidates for docetaxel-based chemotherapy). In support of its use, mitoxantrone has been shown to provide a palliative response in symptomatic patients. In one study by Tannock et al. mitoxantrone was observed to provide significant palliative care in 29% of patients who received mitoxantrone plus prednisone, as compared to 12% who received prednisone alone ( $P = 0.01$ ).<sup>32</sup>

*Radionuclide Therapy:* The use of systemic radiotherapy with samarium-153 or strontium-89 occasionally benefits patients with widely metastatic, symptomatic bone involvement; however, this therapy is usually reserved for candidates who are not responding to palliative chemotherapy and who are not candidates for localized external beam radiotherapy (EBRT).<sup>38,39</sup> The risk of bone marrow suppression, which might influence the ability to administer systemic chemotherapy agents, should be considered before initiation of radionuclide therapy. The use of samarium-153 is further discussed for use in Index Patient 6.

#### **Guideline Statement 9.**

**Clinicians should offer radium-223 to patients with symptoms from bony metastases from mCRPC with good performance status and no prior docetaxel chemotherapy and without known visceral disease. (Standard; Evidence Level Grade B)**

**Discussion:** *Radium-223:* Radium-223 is an  $\alpha$ -emitting radiopharmaceutical capable of inducing double strand DNA breaks in cancer cells while minimizing exposure to surrounding marrow. The use of radium-223 for the treatment on bone metastases relies on the chemical similarity to calcium and the ability of the  $\alpha$ -radiation

and the short-lived decay products of radium-223 to kill cancer cells. The short range of  $\alpha$ -radiation reduces the damage to surrounding healthy tissue creating a more localized effect compared to other radionuclide therapies, such as strontium-89. This is an appropriate treatment for patients with symptomatic bone pain and non-visceral metastases.

A phase III trial with radium-223 in symptomatic men with progressive mCRPC with or without prior docetaxel exposure and no evidence of visceral metastasis reported improvement in median survival; 14.9 months v. 11.3 months (HR 0.695, 95% CI 0.581 – 0.832;  $P=0.00007$ ) in favor of radium-223 over placebo. Time to first SRE improved from 9.8 month with placebo to 15.6 months with radium-223 (HR 0.658, 95% CI 0.522 – 0.830;  $P=0.00037$ ). Significant improvements in QOL measurements were reported in the patients treated with radium-223. Of the 921 patients of this trial, those receiving treatment were given six intravenous injections with a dose of 50 kBq per kilogram of body weight every four weeks.<sup>10</sup> Rates of grade 3 or 4 neutropenia and thrombocytopenia were low at 2.2% and 6.3%, respectively.<sup>40</sup>

#### **Guideline Statement 10.**

***Clinicians should not offer treatment with either estramustine or sipuleucel-T to patients with symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy. (Recommendation; Evidence Level Grade C)***

**Discussion:** *Estramustine:* Estramustine has both cytotoxic and hormonal effects, although the major mechanism of action is as an alkylating agent, which has not shown significant OS advantages. Petrylak et al. showed an OS of 17.5 months for docetaxel + estramustine compared to 15.6 months for mitoxantrone + prednisone ( $P=0.02$ ).<sup>5</sup> However, the survival advantage was similar to Tannock et al for docetaxel without estramustine. Therefore the advantage has been attributed to docetaxel. Given the significant toxicity with estramustine, its use cannot be encouraged.<sup>4</sup> A variety of secondary hormonal deprivation strategies have been studied after failure of initial ADT in mCRPC, such as anti-androgen withdrawal, administration of alternative anti-androgens and use of estrogen derivatives, such as diethylstilbestrol (DES) and estramustine; however, none of these strategies have demonstrated significantly improved OS in the symptomatic, pre-chemotherapy mCRPC setting.

*Sipuleucel-T:* The use of sipuleucel-T immunotherapy is not recommended in symptomatic disease that necessitates narcotic use, consistent with the FDA indication for this compound. Thus, sipuleucel-T

currently may be considered only for patients with asymptomatic or minimally symptomatic mCRPC and is most appropriate for Index Patient 2, as previously discussed.<sup>8</sup> Patients with large tumor burdens, those with visceral disease and those with more aggressive disease (predicted survival  $< 12$  months) are less likely to respond to immunotherapy.

#### **Index Patient 4**

Symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy

Clinical trials have generally excluded patients with a poor performance status (ECOG 3-4) from participation. Thus, most data regarding management of such patients is extrapolated from randomized trials of eligible patients who had a better performance status, as well as from some smaller trials and registries. Even a phase III clinical trial that was presumptively designed for a population considered “unfit” for docetaxel (ALSYMPCA to evaluate radium-223) still only allowed a performance status of ECOG 0-1. However, treatments with acceptable safety profiles do exist and should be considered, even in poor performance status patients. This is especially true in those patients in whom the poor performance status may be considered to be directly related to the cancer itself and thus whose status might improve with effective treatment. Treatments must be individually tailored in these patients after a careful discussion of risks and benefits with particular attention to patient QOL.

#### **Guideline Statement 11.**

***Clinicians may offer treatment with abiraterone + prednisone to patients with symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy. (Option; Evidence Level Grade C)***

**Discussion:** In the previously discussed COU-AA-302 study,<sup>31</sup> OS did not meet the prespecified boundary for significance at the early point of unblinding. Thus, though survival trend is better with abiraterone + prednisone, it remains unclear if abiraterone + prednisone improves OS. Nevertheless, the FDA approved the label for use of abiraterone + prednisone in mCRPC independent of docetaxel treatment. Notably, COU-AA-302 was administered only in good performance status patients, but it is the panel’s opinion that abiraterone + prednisone would be a reasonable alternative to chemotherapy for patients even with a poor performance status.

#### **Guideline Statement 12.**

***Clinicians may offer treatment with ketoconazole+ steroid or radionuclide therapy to***

**patients with symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy who are unable or unwilling to receive abiraterone + prednisone. (Option; Evidence Level Grade C)**

**Discussion:** *Ketoconazole:* Ketoconazole has been demonstrated to have anti-cancer effects<sup>36</sup> in the setting of mCRPC and could be a viable alternative, in particular if abiraterone + prednisone is unavailable. It is important to recognize that ketoconazole has a worse side effect profile, as previously stated in the discussion of Index Patient 1.

*Radionuclide Therapy:* Samarium-153 and strontium-89 have not shown a survival benefit but may offer palliative benefit in patients symptomatic with bone pain. These are further discussed under Index Patient 6. The use of radium-223 in this Index Patient is addressed below.

**Guideline Statement 13.**

**Clinicians may offer docetaxel or mitoxantrone chemotherapy to patients with symptomatic mCRPC with poor performance status and no prior docetaxel chemotherapy in select cases, specifically when the performance status is directly related to the cancer. (Expert Opinion)**

**Discussion:** Patients with mCRPC may have a poor performance status for multiple reasons, but the two major possibilities are related to the cancer itself or because of non-prostate cancer related causes. For instance, a patient who was previously active and healthy whose cancer progresses rapidly in bone and liver may develop severe pain, weakness, weight loss and other symptoms thought to be directly related to the progression of cancer. This patient may benefit from treatment. An alternative patient may be one in whom a long history of chronic disorders, such as diabetes, heart disease, arthritis, cirrhosis and other conditions may be underlying the new diagnosis of prostate cancer. In this case, effective treatment of his cancer would not improve any of his underlying conditions.

*Docetaxel:* Docetaxel is considered the standard first-line therapy in mCRPC and has demonstrated both a survival benefit as well as a palliative benefit in symptomatic disease. Most patients with a poor performance status are not considered qualified candidates for chemotherapy, but it is possible that some patients whose cancers are mostly contributing to their disability may benefit from anti-cancer treatment. Such an approach must be undertaken cautiously by a qualified physician experienced in the administration of chemotherapy. Dosage and schedule modifications

might be considered for individual patients to make this more tolerable.

*Mitoxantrone:* Mitoxantrone was approved in 1996 based on two randomized trials that demonstrated a palliative benefit in symptomatic mCRPC.<sup>32,41</sup> No survival benefit has been seen with mitoxantrone. However, it could be considered as an alternative option to docetaxel or potentially as a second-line therapy in men with symptomatic disease and a poor performance status. Like all of the trials mentioned, no clinical trials allowed patients with poor performance status, so caution must be taken. If the poor performance status is not related to cancer progression, then systemic chemotherapy of any kind is not recommended.

**Guideline Statement 14.**

**Clinicians may offer radium-223 to patients with symptoms from bony metastases from mCRPC with poor performance status and no prior docetaxel chemotherapy and without known visceral disease in select cases, specifically when the performance status is directly related to symptoms related to bone metastases. (Expert Opinion)**

**Discussion:** Radium-223 may be offered for patients with symptomatic bone pain and non-visceral metastases. Radium-223 has showed survival benefit in patients with good performance status. If it is believed that the poor performance status of Index Patient 4 is due to symptomatic bone pain, radium-223 may also be beneficial to these patients.

**Guideline Statement 15.**

**Clinicians should not offer sipuleucel-T to patients with symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy. (Recommendation; Evidence Level Grade C)**

**Discussion:** In subsequent analyses of the IMPACT trial, it appears that the survival benefit associated with its use does not appear until six months after therapy.<sup>8</sup> Sipuleucel-T appears to benefit patients with a lower disease burden and better performance status. Most patients in IMPACT had not received prior chemotherapy (18.2% of patients had received prior docetaxel chemotherapy). All patients in the IMPACT trial were either ECOG 0 or 1, and over 80% of patients were ECOG 0.<sup>8</sup>

Thus, the benefit of using sipuleucel-T in men with mCRPC and a shorter life expectancy appears to be limited. Patients with very symptomatic disease and a poor performance status would be unlikely to gain a

significant survival benefit from the use of sipuleucel-T and should be directed towards alternative options.

### **Index Patient 5**

Symptomatic, mCRPC with good performance status and prior docetaxel chemotherapy

As patients with prostate cancer receive hormonal therapy earlier in the course of the disease (frequently for non-metastatic disease), they may actually develop castration-resistant disease (based on serologic progression) with non-metastatic or asymptomatic metastatic disease. Thus, additional agents, including docetaxel chemotherapy may be administered earlier in the course of metastatic disease. These trends have resulted in a population of mCRPC patients who have completed docetaxel and may continue to be asymptomatic or minimally-symptomatic with an excellent performance status. While such patients may be healthy enough to receive a number of subsequent therapies, a focus of therapy should also be to maintain their excellent performance status without significant toxicity from additional therapy. It is in this context that providers should choose from a number of additional therapies to offer to this patient population.

### **Guideline Statement 16.**

***Clinicians should offer treatment with abiraterone + prednisone, cabazitaxel or enzalutamide to patients with mCRPC with good performance status who received prior docetaxel chemotherapy. If the patient received abiraterone + prednisone prior to docetaxel chemotherapy, they should be offered cabazitaxel or enzalutamide. [Standard; Evidence Level Grade A (abiraterone) / B (cabazitaxel)/ A (enzalutamide)]***

**Discussion:** The trend over the past six to seven years has been to use docetaxel earlier in the course of treatment for a patient with castration-resistant disease, perhaps in those with minimal symptoms or even the asymptomatic patient with evidence of serologic or radiographic progression. The result is that many patients who have received and failed docetaxel have an excellent performance status and some may remain asymptomatic from their disease. Thus, the risk/benefit ratio of subsequent therapy and the desire to maintain an excellent QOL should certainly be of primary concern when selecting additional therapies post-docetaxel. In this light, abiraterone + prednisone and enzalutamide appear to provide clinical benefit equivalent to (if not superior to) additional intravenous chemotherapy with an agent such as cabazitaxel. Abiraterone + prednisone and enzalutamide have significantly less acute toxicity and no apparent cumulative toxicity in patients receiving these agents

for prolonged periods. This is in contradistinction to cabazitaxel, which may show cumulative bone marrow toxicity (manifested by pancytopenia) and also cumulative neurotoxicity, particularly in patients with some underlying peripheral neuropathy from their prior docetaxel. Both abiraterone + prednisone and enzalutamide represent excellent treatment options for such a patient. While there have been no randomized trials comparing these agents and little information exists regarding appropriate sequencing of these drugs, patients may have prolonged responses to either or both of these agents. With the FDA's recent expansion of the label indication for abiraterone + prednisone to the pre-chemotherapy setting based on the results of a phase III clinical trial,<sup>31</sup> patients will have increasingly already been exposed to and progressed on abiraterone + prednisone by the time they reach the post-docetaxel setting, making enzalutamide a preferable option compared to cabazitaxel.

**Abiraterone + prednisone:** In a phase III trial (COU-AA-301), 1,195 patients who had failed docetaxel received 1,000 mg abiraterone + prednisone or placebo. At a median of 12.8 months, OS and PFS favored the abiraterone + prednisone cohort (14.8 months v.10.9 months; hazard ratio, 0.65; P<0.001 and 5.6 months v. 3.6 months; P<0.001, respectively).<sup>7</sup> As previously noted, abiraterone + prednisone was well tolerated during clinical trial but did show an increase in adverse events and specifically those side effects related to mineralocorticoid excess.

**Cabazitaxel:** Cabazitaxel is another tubulin-binding taxane chosen for clinical development because of preclinical activity in tumor models resistant to other taxanes. An open-label, randomized phase III trial compared cabazitaxel at 25 mg/M<sup>2</sup> intravenously with oral prednisone versus mitoxantrone at 12 mg/M<sup>2</sup> intravenously with the same dose of prednisone, both administered on an every three week basis.<sup>9</sup> In this trial 755 patients who had received prior docetaxel were randomized, and the group receiving cabazitaxel demonstrated improved OS (15.1 months v 12.7 months) and improved PFS (2.8 months v 1.4 months). Cabazitaxel resulted in more-clinically-significant diarrhea, but its primary toxicity is hematologic with 82% of patients developing grade 3 or 4 neutropenia, 8% developing febrile neutropenia and 5% resulting in death. The FDA label indication for this drug recommends prophylactic neutrophil growth factor support in those patients most susceptible to neutropenia, including older individuals and those with significant prior radiotherapy. Because of the need for intravenous administration, the more modest clinical benefit and the higher rates of significant toxicity, cabazitaxel is ranked below abiraterone + prednisone and enzalutamide for this group of patients.

**Enzalutamide:** Enzalutamide is a novel AR signaling inhibitor. Enzalutamide is a competitive inhibitor of androgen binding and also inhibits nuclear translocation of the AR, DNA binding and coactivator recruitment.<sup>42</sup> This drug binds AR with a five- to eight-fold higher affinity than bicalutamide, inhibits AR nuclear translocation, and has reduced agonist activity, all distinguishing it from the three non-steroidal AR antagonists used in current clinical practice.<sup>42</sup>

Phase I/II data showed serologic and radiographic responses in both chemo-naïve patients as well as those who had received prior chemotherapy.<sup>43</sup> The subsequent double-blind, placebo-controlled AFFIRM phase III trial was performed in 1,199 patients who had received prior docetaxel therapy.<sup>6</sup> Patients received either enzalutamide 160 mg/day orally or placebo, and OS, the primary endpoint, favored enzalutamide (18.4 months v 13.6 months). There was also statistical superiority of enzalutamide for all secondary endpoints, including percentage of patients with 50% PSA reduction, soft-tissue response rate, QOL response rate, time to PSA progression, radiographic PFS and time to first SRE. Toxicity from enzalutamide was related primarily to fatigue, diarrhea and hot flashes, although 5 of 800 patients receiving the drug developed seizure activity. This drug was approved by the FDA in August of 2012 and represents another highly active oral agent with minimal toxicity available to these patients.

#### **Guideline Statement 17.**

**Clinicians may offer ketoconazole + steroid to patients with mCRPC with good performance status who received prior docetaxel if abiraterone + prednisone, cabazitaxel or enzalutamide is unavailable. (Option; Evidence Level Grade C)**

**Discussion:** A number of clinical trials have established the efficacy and toxicity of high-dose ketoconazole in this setting,<sup>27,36,44-48</sup> with as many as 50% of patients showing a > 50% drop in PSA, fewer bidimensionally measurable disease responses and a median time to progression of five to eight months. One study has suggested that 1) prior response to an antiandrogen; 2) pre-treatment PSA doubling time; and 3) extent of disease may be associated with the likelihood of clinical response to this therapy.<sup>46</sup> Although ketoconazole likely has a lower response rate, a shorter time to progression and higher incidence of significant toxicity than abiraterone + prednisone, it remains a viable alternative for patients unable to obtain abiraterone + prednisone.

#### **Guideline Statement 18.**

**Clinicians may offer retreatment with docetaxel to patients with mCRPC with good performance**

**status who were benefitting at the time of discontinuation (due to reversible side effects) of docetaxel chemotherapy. (Option; Evidence Level Grade C)**

**Discussion:** Much of the benefit of docetaxel in the mCRPC patient is seen in improvement of survival and QOL. However, prolonged, continuous therapy with docetaxel can result in cumulative, progressive, non-hematologic toxicity (e.g. neuropathy) that may more than counterbalance any potential serologic, radiographic or symptomatic benefit the patient may be receiving from the drug. In an effort to prolong the overall period of disease control with docetaxel, to allow reversible side effects to improve and to maximize overall QOL by spending as much time off chemotherapy as possible, the use of intermittent therapy with built-in drug holidays has become a common practice. Non-randomized data<sup>49-52</sup> as well as one randomized trial<sup>53</sup> suggests that a minority of patients may retain sensitivity to the drug with multiple discontinuous periods of administration. It is apparent that those drug holidays may last, on average, four to five months and that subsequent non-treatment periods might also last a number of months. It is logical to assume that patients with the most dramatic clinical benefit from prior docetaxel and with a more prolonged period off therapy prior to reinstitution are more likely to benefit from additional treatment with the same drug. Patients with these characteristics and who have recovered from prior toxicity may be considered for a re-trial of docetaxel before this drug is discarded from the armamentarium.

#### **Guideline Statement 19.**

**Clinicians should offer radium-223 to patients with symptoms from bony metastases from mCRPC with good performance status who received prior docetaxel chemotherapy and without known visceral disease. (Standard; Evidence Level Grade B)**

**Discussion:** During the course of cancer treatment, bone marrow can become infiltrated by the cancer. Chemotherapeutic agents, such as docetaxel, can suppress bone marrow function while being used to extend survival and improve quality of life. Radium-223 was shown to be an effective therapy in the previously discussed Parker et al. study<sup>10</sup> in which 57% of patients had previously received chemotherapy. As with other treatments, such as EBRT, side effects can include anemia and thrombocytopenia. Those patients who have previously received chemotherapy are at greater risk for such side effects compared to chemotherapy-naïve patients.

**Index Patient 6**

Symptomatic, mCRPC with poor performance status and prior docetaxel chemotherapy

The American Society of Clinical Oncology (ASCO) has posted recommendations regarding treatment for patients with advanced solid tumors; particularly in the last months of life. ASCO advocates for an increasing emphasis on a patient's QOL and concentrates on symptom management. Treatment given in the last months of life may delay access to end of life care, increase costs and add unnecessary symptom management. Patients with poor performance status (ECOG 3 or 4) should not be offered further treatment (<https://connection.asco.org/Magazine/Article/ID/3190/Choosing-Wisely-Constructing-a-Top-Five-List-in-Oncology.aspx>).

**Guideline Statement 20.**

**Clinicians should offer palliative care to patients with mCRPC with poor performance status who received prior docetaxel chemotherapy. Alternatively, for selected patients, clinicians may offer treatment with abiraterone + prednisone, enzalutamide, ketoconazole + steroid or radionuclide therapy. (Expert Opinion)**

**Discussion:** Palliative care is an interdisciplinary, holistic approach to managing an advanced disease such as prostate cancer with a guarded prognosis. It can include controlling symptoms that are physical, psychological, spiritual and social. The goal of palliation is to prevent and relieve suffering and to support the best possible QOL for the patient and family. Advanced prostate cancer can be debilitating with bone pain, fatigue and weight loss. Palliative radiotherapy can be an option for controlling bone pain in some patients. An increasing dependence upon others and a feeling of losing control can contribute to anxiety and depression. Other symptoms include urinary outflow obstruction, weakness secondary to spinal cord compression, lymphedema and anemia. Evaluation and treatment should be comprehensive and patient centered, focusing on the goals of the individual patient as well as the patient's family. Comprehensive palliative care often requires a multidisciplinary approach where various providers of differing expertise assess and treat the complex needs of the advanced disease prostate cancer patient.<sup>54,55</sup>

**Abiraterone + prednisone:** Abiraterone is for **patients who have CRPC** that is resistant to medical or surgical treatments and who **have received prior docetaxel chemotherapy**. Method of action and dosing information are previously referenced.

**Enzalutamide:** Enzalutamide is indicated for the

treatment of patients with mCRPC who have previously received docetaxel. The previously discussed AFFIRM study found that enzalutamide significantly prolonged the survival of men with mCRPC after chemotherapy. Method of action and dosing information are previously referenced.

**Ketoconazole:** Ketoconazole provides an available but fairly toxic treatment plan for patients with mCRPC who have received prior docetaxel chemotherapy with poor performance status. Method of action and dosing information are previously referenced.

**Radionuclide Therapy:** One example of a Phase III randomized clinical trial of radioactive samarium-153 (<sup>153</sup>Sm) lexidronam versus nonradioactive <sup>153</sup>Sm-lexidronam for palliation of bone pain in patients with CRPC is by Sartor (2004).<sup>56</sup> A total of 152 men with painful bone metastases were enrolled in this prospective, randomized, double-blind trial. Patients were randomized (2:1) to the radioactive <sup>153</sup>Sm-lexidronam agent. Inclusion criteria were advanced prostate cancer progressing despite medical or surgical orchiectomy, a positive bone scan, pain scores of greater than 30mm on a 100mm visual analog scale or the use of opioid analgesics in daily doses equivalent to 60mg oral morphine, a Karnofsky performance status of less than 50% and life expectancy of greater than four months. Exclusion criteria were hormonal treatment initiated within eight weeks of dosing or radiotherapy administered within six weeks, pathologic fractures, spinal cord compression, prior hemibody irradiation, inadequate hematological, renal or liver function, allergies to phosphate compounds and prior exposure to radiopharmaceutical agents or bisphosphonates within six months of dosing. Patients completed pain and analgesic diaries twice daily. Blinded medications were given intravenously; the study was unblinded after four weeks when 28 of 52 placebo patients had not achieved satisfactory pain relief by week four; 22 of 28 chose to receive open label treatment with radioactive <sup>153</sup>Sm-lexidronam. The authors concluded that 1 mCi/kg <sup>153</sup>Sm-lexidronam is safe and effective for palliation of painful bone metastases in patients with hormone-refractory prostate cancer. Side effects included mild bone marrow suppression. The mean nadir white blood cell and platelet count (three to four weeks after treatment) was 3,800/ $\mu$ L and 127,000/ $\mu$ L, respectively. Counts recovered to baseline after approximately eight weeks. No grade 4 decreases in either platelets or white blood cells were documented.

Multiple non-randomized trials have been done with Samarium-153 alone<sup>57,58</sup> with unclear adverse events and outcomes. Other studies included Samarium-153 with docetaxel;<sup>59,60</sup> these studies were also unclear in outcomes or adverse events. Studies looking at radium-223 have focused on those patients with good

performance status, and there is no data indicating an advantage over standard radiopharmaceuticals in this patient population.

**Guideline Statement 21.**

***Clinicians should not offer systemic chemotherapy or immunotherapy to patients with mCRPC with poor performance status who received prior docetaxel chemotherapy. (Expert Opinion)***

**Discussion:** There is insufficient evidence demonstrating a benefit in this patient population. The potential for harm greatly outweighs the potential benefit, so these treatments should not be offered.

**Guideline Statements on Bone Health (not specific to any one index patient)**

Several factors conspire to place the average patient with metastatic prostate cancer at a higher risk of bone complications. First, the median age of onset of the disease is in the late 60s, meaning that the average patient with metastatic disease may be in the 70s (or beyond), clearly a population at risk of physiologic, age-related decreases in bone mineral density. Secondly, a primary therapeutic intervention in patients with recurrent disease, ADT, is associated with progressive loss of bone mineral density, not infrequently to the point of measurable osteopenia or frank osteoporosis, increasing the patient's fracture risk, even in patients with non-metastatic disease.<sup>61,62</sup> Finally, in patients with advanced disease, bones are the most common site of metastatic disease, with as many as 70% of patients at some point in their course demonstrating evidence of disease in this site.

**Guideline Statement 22.**

***Clinicians should offer preventative treatment (e.g. supplemental calcium, vitamin D) for fractures and skeletal related events to CRPC patients. (Recommendation; Evidence Level Grade C)***

**Discussion:** Published data on the use of supplemental calcium and vitamin D to minimize bone mineral density loss in individuals on hormonal therapy with or without bony metastatic disease are confusing, and the discussion contentious. Part of the confusion arises from different populations of patients being studied (elderly patients without cancer, post-menopausal women, prostate cancer patients on ADT, etc.) as well as differences in the doses of the supplements and the inability to model vitamin D's physiologic effect on intestinal absorption of calcium in the laboratory setting.

**Vitamin D:** A meta-analysis of randomized controlled

trials in over 9,000 patients 60 years of age or older has reported a reduction in the relative risk of hip fracture of 26% (compared to calcium alone or placebo) and of non-vertebral fractures by 23%, although these reductions were only observed with higher doses of vitamin D (700-800 IU/day).<sup>63</sup> There was no benefit observed at 400 IU/day, a dose commonly incorporated into multivitamin preparations. In another study summarizing the results of 12 clinical trials of calcium and vitamin D supplementation in males undergoing ADT for prostate cancer, doses of vitamin D in the 200-500 IU/day range were inadequate to prevent loss of bone mineral density.<sup>62</sup>

**Calcium:** Since hypocalcemia requiring dose modification or abandonment is a not-uncommon side effect of both zoledronic acid and denosumab, it seems reasonable to offer supplemental calcium to individuals receiving these drugs in an effort to maintain supportive therapy. However, it would appear that calcium supplementation alone (500-1,000 mg/day) cannot prevent bone mineral density loss from ADT.<sup>64</sup> Also, calcium supplementation may not be innocuous, as epidemiologic studies have suggested a relationship between calcium intake and the risk of subsequent cardiovascular disease<sup>65,66</sup> and prostate cancer risk including fatal prostate cancer, though conflicting data exist.<sup>67,68</sup>

With these caveats, it is impossible to make firm recommendations regarding the use of supplemental calcium and vitamin D in prostate cancer patients who will experience bone mineral density loss from long-term ADT. Practitioners who choose to recommend these supplements should be aware of the potential risks and benefits.

**Guideline Statement 23.**

***Clinicians may choose either denosumab or zoledronic acid when selecting a preventative treatment for skeletal related events for mCRPC patients with bony metastases. (Option; Evidence Level Grade C)***

**Discussion:** *Denosumab:* RANK –ligand and its inhibitors are important molecules involved in bone turnover. RANKL is an important driver of osteoclast function and survival. Denosumab is a human monoclonal antibody directed against RANKL and inhibits osteoclast-mediated bone destruction. In patients with non-metastatic disease receiving ADT, denosumab has been shown to actually increase bone mineral density at the total hip, femoral neck and lumbar spine and decrease the incidence of vertebral fractures.<sup>69</sup> In a subsequent randomized trial in over 1,900 patients with mCRPC, subcutaneous denosumab demonstrated a longer time to first SRE compared to

intravenous zoledronic acid given on an every four-week schedule (20.7 months v 17.1 months).<sup>70</sup> Denosumab resulted in more significant hypocalcemia (13% of patients v. 6%). For this reason when prescribing denosumab it is recommended to include supplemental calcium and to monitor serum calcium level. While denosumab does not need to be dose adjusted based on serum creatinine, 22% of patients receiving zoledronic acid required baseline dose adjustment based on renal function, and an additional 15% required additional dose modifications due to serum creatinine while on study. Osteonecrosis of the jaw was uncommon in both arms (2% denosumab, 1% zoledronic acid). Based on these data, both denosumab and zoledronic acid can be considered options, with denosumab providing slightly superior efficacy results in a head-to-head comparison, and therefore is listed as the first option.

**Zoledronic acid:** Bisphosphonates as a class are potent inhibitors of bone resorption, and several drugs in this class have previously been shown to decrease the incidence of skeletal complications with breast cancer and multiple myeloma. Zoledronic acid is the only bisphosphonate to demonstrate a beneficial effect in patients with mCRPC. In a phase III randomized trial<sup>71</sup> 4 mg of zoledronic acid given intravenously every three weeks: 1) decreased the incidence of SREs by 36%, and 2) longer therapy (up to 24 months) appears to confer continued benefit, even in patients who have experienced one SRE, when compared to placebo. The toxicity of this therapy includes a small incidence of osteonecrosis of the jaw, hypocalcemia and nephrotoxicity. These latter two mandate that serum creatinine and serum calcium be obtained prior to each dose with appropriate dose modifications for abnormal results.

**Radionuclide Therapy:** Intravenous radionuclides have been developed in an attempt to palliate patients with painful bony metastases. Initially strontium-89 was developed and provided short-term improvement in pain in a minority of patients but at the expense of moderate to severe bone marrow toxicity, likely related to its prolonged half-life.<sup>72-74</sup> Samarium-153 has been shown in two randomized trials to provide palliation to patients with painful bony metastases and to have less severe and more transient hematologic toxicity, likely related to its shorter half-life,<sup>75,76</sup> which also results in the possibility of giving multiple doses to patients safely.<sup>77</sup> The toxicity profile alone would result in the selection of samarium-153 over strontium-89 in this group of patients.

### Future Directions

Over the past 15 years there has been un-paralleled scientific progress and investment in drug development

for patients with mCRPC. As a direct result of these studies, several lines of systemic therapies have been FDA approved for use in mCRPC on grounds of pain palliation, minimizing disease adverse effects and prolonging survival.

**Ongoing Research.** In addition to agents discussed above, several other drugs are in the pipeline:

*Completed, unpublished Phase III trials as of guideline publication:*

**Enzalutamide:** The Phase III PREVAIL trial evaluating enzalutamide versus placebo in chemotherapy-naïve men with mCRPC was stopped early by the Data Safety Monitoring Committee after an interim analysis revealed improvements in overall survival (HR 0.706, 95% CI [0.60-0.84]) and radiographic progression-free survival (HR 0.186, 95% CI [0.15-0.23]) for the enzalutamide arm. 1,717 men with asymptomatic or mildly symptomatic mCRPC (including some with visceral metastases) were randomly assigned to placebo versus 160 mg/day of enzalutamide. The final publication of this trial was still pending at the time of this guideline update.

*Ongoing Phase III trials as of guideline publication:*

**Orteronel:** Orteronel is a CYP17A inhibitor but is more specifically a 17,20-lyase inhibitor. It is currently being tested in a phase III trial comparing orteronel and prednisone to placebo and prednisone ([NCT01193244](#)).

**Tasquinomod:** Tasquinomod is an orally active quinoline -3-carboxamide. It has anti-angiogenic and anti-tumor properties and is currently in ongoing phase III testing to assess men with bone-metastatic disease to assess its impact on survival ([NCT01234311](#)).

**Immunotherapy:** Novel vaccine strategies to harness the immune system are being tested, such as PROSTVAC in asymptomatic, chemotherapy-naïve men with mCRPC in a phase III study randomizing participants to PROSTVAC with or without GM-CSF or to placebo ([NCT01322490](#)). Other immune based strategies include inhibition of immune check points using Ipilimumab, which is a monoclonal anti-CTLA4 antibody that binds to the CTLA-4 receptor on T cells, blocking CTLA4 and, in turn, activating T-cell anti-tumor activity. A phase III study comparing ipilimumab to placebo is ongoing ([NCT01057810](#)).

**Custirsen:** Custirsen inhibits the production of clusterin, a protein associated with treatment resistance in a number of cancers, including prostate cancer. Adding agents with novel or different mechanisms of action to a docetaxel-backbone remains an area of significant interest. Results are pending from the phase III trials combining docetaxel + prednisone with custirsen,

([NCT01188187](#)), and another phase III trial was recently activated comparing cabazitaxel + prednisone with or without custirsen ([NCT01578655](#)).

*Cabozantinib*: Cabozantinib is a MET and VEGFR2 oral TKI. In a phase II trial, it had promising anti-tumor activity, particularly in patients with bone metastasis.<sup>78</sup> It is currently in Phase III trials in the post docetaxel setting ([NCT01605227](#) and [NCT01522443](#)).

**Future Research.** The impact on survival in mCRPC from each of these individual agents thus far continues to be modest, being measured only in months. To further impact outcomes therapy, development in this stage of disease must focus on the totality of disease biology integrating a comprehensive molecular understanding of castration resistance and investigating mechanisms of resistance to current therapies so as to better guide future treatment development. Continued investments in discovery, investigation and validation of important new candidate targets is needed.

One of the glaring deficiencies in prostate cancer drug development, by comparison to several other solid tumors, has been the lack of predictive biomarkers to help better personalize therapy. This is especially important if we are to optimize risk/benefit, particularly given that a significant percentage of patients do not benefit or have small benefits from current FDA approved agents.

In addition to the continued investigation of new agents in the mCRPC population, it is critical that we prospectively define the optimal sequence of approved treatments in order to guide proper use taking into account efficacy and cost-effectiveness, particularly for agents that target similar pathways. Furthermore, maximizing the antitumor effect by investigating scientifically rational combinations should be an area of high priority.

Over the past decade there have been considerable advances in our biologic understanding of mCRPC that have led to an explosion of novel treatments. Unfortunately, mCRPC remains a fatal disease. Hence, research to maximize the efficacy of ADT with the use of even more effective agents and investigating alternative combination strategies in well-designed and supported clinical trials is critical.

## References

## References

1. Siegel R, Naishadham D and Jemal A et al: Cancer statistics, 2012. *CA Cancer J Clin* 2012; **62**: 10.
2. Montgomery RB, Mostaghel EA, Vessella R et al: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res* 2008; **68**: 4447.
3. Mohler JL, Titus MA, Bai S et al: Activation of the androgen receptor by intratumoral bioconversion of androstenediol to dihydrotestosterone in prostate cancer. *Cancer Res* 2011; **71**: 1486.
4. Tannock IF, de Wit R, Berry WR et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Eng J Med* 2004; **351**: 1502.
5. Petrylak DP, Tangen CM, Hussain MHA et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004; **351**: 1513.
6. Scher HI, Fizazi K, Saad F et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Eng J Med* 2012; **367**: 1187.
7. de Bono JS, Logothetis CJ, Molina A et al: Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011; **364**: 1995.
8. Kantoff PW, Higano CS, Shore ND et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010; **363**: 411.
9. de Bono JS, Oudard S, Ozguroglu M et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. *Lancet* 2010; **376**: 1147.
10. Parker C, Nilsson S, Heinrich D et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; **369**: 213.
11. Smith MR, Saad F, Coleman R et al: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. *Lancet* 2012; **379**: 39.
12. Faraday M, Hubbard H, Kosiak B et al: Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. *BJU Int* 2009; **104**: 294.
13. Atkins D, Best D, Briss PA et al: GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ* 2004; **328**: 1490.
14. Balshem H, Helfand M, Schünemann HJ et al: GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011; **64**: 401.
15. Hsu C and Sandford BA: The Delphi Technique: Making Sense of Consensus. *Practical Assessment, Research & Evaluation* 2007; **12**: 1.
16. Scher HI, Halabi S, Tannock I et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol* 2008; **26**: 1148.
17. Fujii Y, Kawakami S, Masuda H et al: Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. *BJU Int* 2006; **97**: 1184.
18. Fujikawa K, Matsui Y, Fukuzawa S et al: Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate cancer. *Eur Urol* 2000; **37**: 218.
19. Kojima S, Suzuki H, Akakura K et al: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. *J Urol* **171**: 679.
20. Miyake H, Hara I and Eto H: Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. *BJU Int* 2005; **96**: 791.
21. Nakabayashi M, Regan MM, Lifsey D et al: Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC). *J Clin Oncol* 2005; **23**: 4683.
22. Nishimura K, Arichi N, Tokugawa S et al: Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. *Int J Urol* 2007; **14**: 264.
23. Harris KA, Weinberg V, Bok RA et al: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. *J Urol* 2002; **168**: 542.
24. Nakabayashi M, Xie W, Regan MM et al: Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. *Cancer* 2006; **107**: 975.
25. Ngo LS, Yeo A, Wong AS et al: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. *Ann Acad Med Singapore* 2007; **36**: 811.
26. Scholtz M, Jennrich R, Strum S et al: Long-term outcome in men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. *J Urol* 2005; **173**: 1947.
27. Small EJ, Baron A and Bok R: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. *Cancer* 1997; **80**: 1755.
28. Taplin ME, Regan MM, Ko YJ et al: Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic

## References

- castration-resistant prostate cancer. *Clin Cancer Res* 2009; **15**: 7099.
29. Wilkinson S and Chodak G: An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. *Eur Urol* 2004; **45**: 581.
  30. Attard G, Reid AHM, A'Hern R et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol* 2009; **27**: 3742.
  31. Ryan CJ, Smith MR, de Bono JS et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013; **368**: 138.
  32. Tannock IF, Osoba D, Stockler MR et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* 1996; **14**: 1756.
  33. Oliver RTD, Williams G, Paris AMI et al: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. *Urology* 1997; **49**: 79.
  34. Nishiyama T and Terunuma M: Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer. *Urol Int* 2000; **65**: 28.
  35. Sartor AO, Tangen CM, Hussain MG et al: Androgen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). *Cancer* 2008; **112**: 2393.
  36. Small EJ, Halabi S, Dawson NA et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). *J Clin Oncol* 2004; **22**: 1025.
  37. Berthold DR, Pond GR, Soban F et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. *J Clin Oncol* 2008; **28**: 242.
  38. Finlay IG, Mason MD and Shelley M: Radioisotopes for the palliation of metastatic bone cancer: a systematic review. *Lancet Oncol* 2005; **6**: 392.
  39. Pandit-Taskar N, Batraki M and Divgi CR: Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. *J Nucl Med* 2004; **45**: 1358.
  40. Parker C, Coleman RE, Nilsson S et al: Updated survival, quality of life (QOL), and safety data of radium-223 chloride (RA-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). *Ann of Oncol* 2012; **23**: ix294.
  41. Kantoff PW, Halabi S, Conaway M et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. *J Clin Oncol* 1999; **17**: 2506.
  42. Tran C, Ouk S, Clegg NJ et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* 2009; **324**: 787.
  43. Scher HI, Beer TM, Higano CS et al: Antitumor activity of MDV-3100 in castration-resistant prostate cancer: a phase 1-2 study. *Lancet* 2010; **375**:1437.
  44. Harris KA, Bok RA, Kakefuda M et al: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. *J Urol* 2002; **168**: 5425.
  45. Johnson DE, Babiian RJ, von Eschenbach AC et al: Ketoconazole therapy for hormonally refractive metastatic prostate cancer. *Urology* 1988; **31**: 132.
  46. Keizman D, Huang P, Carducci MA et al: Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. *Prostate* 2012; **72**: 461.
  47. Ryan CJ, Weinberg V, Rosenberg J et al: Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. *J Urol* 2007; **178**: 2372.
  48. Small EJ, Baron AD, Fippin L et al: Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. *J Urol* 1997; **157**: 1204.
  49. Beer TM, Garzotto M, Henner WD et al: Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. *Br J Cancer* 2004; **91**: 1425.
  50. Lin A, Ryan CJ and Small EJ: Intermittent chemotherapy for metastatic hormone refractory prostate cancer. *Crit Rev Onc/Hem* 2007; **61**: 243.
  51. Mountzios I, Bournakis E, Efstathiou E et al: Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. *Urology* 2011; **77**: 682.
  52. Soga N, Kato M, Nishikawa K et al: Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. *Int J Clin Oncol* 2009; **14**: 130.
  53. Beer TM, Ryan CJ, Venner PM et al: Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. *Cancer* 2008; **112**: 326.
  54. de Bono DJ: Integration of palliative medicine into routine oncological care: what does the evidence show us? *J Oncol Pract* 2011; **7**: 1.
  55. Thompson JC, Wood J and Feuer D: Prostate cancer: palliative care and pain relief. *Brit Med Bull* 2007; **83**: 341.

## References

56. Sartor O: Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. *Rev Urol* 2004; **6**: s3.
57. Ripamonti C, Fagnoni E, Campa T et al: Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. *Support Care Cancer* 2007; **15**: 339.
58. Dolezal J, Vizda J and Odrazka K: Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. *Urol Int* 2007; **78**: 50.
59. Fizazi K, Beuzeboc P, Lumbroso J et al: Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. *J Clin Oncol* 2009; **27**: 2429.
60. Suttman H, Grgic A, Lehmann J et al: Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. *Cancer Biother Radiopharm* 2008; **23**: 609.
61. Smith MR, Lee WC, Brandman J et al: Gonadotropin-Releasing Hormone Agonists and Fracture Risk; a Claims-Based Cohort Study of Men with Nonmetastatic Prostate Cancer. *J Clin Oncol* 2005; **23**: 7897.
62. Shahinian VB, Kuo YF, Freeman JL et al: Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 2005; **352**: 154.
63. Bischoff-Ferrari HA, Willett WC, Wong JB et al: Fracture prevention with vitamin d supplementation. *JAMA* 2005; **293**: 2257.
64. Datta M and Schwartz GG: Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer: a critical review. *Oncologist* 2012; **17**: 1171.
65. Lind L, Skarfors E, Berglund L et al: Serum Calcium: A new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. *J Clin Epidemiol* 1997; **50**: 967.
66. Li K, Kaaks R, Linseisen J et al: Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg Cohort of the European Prospective Investigation into Cancer and Nutrition Study (EPIC-Heidelberg). *Heart* 2012; **98**: 920.
67. Schwartz GG and Skinner HG: A prospective study of total and ionized serum calcium and time to fatal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2012; **21**: 1768.
68. Skinner HG and Schwartz GG: Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 2302.
69. Smith MR, Egerdie B, Hernandez Toriz N et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Eng J Med* 2009; **361**: 745.
70. Fizazi K, Carducci M, Smith M et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. *Lancet* 2011; **377**: 813.
71. Saad F, Gleason DM, Murray R et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. *J Natl Cancer Inst* 2004; **96**: 879.
72. Laing AH, Ackery DM, Bayly RJ et al: Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. *Br J Radiol* 1991; **64**: 816.
73. Lewington VJ, McEwan AJ, Ackery DM et al: A Prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer* 1991; **27**: 954.
74. Lee CK, Aeppli DM, Unger J et al: Strontium-89 chloride (metastron) for palliative treatment of bony metastases: The University of Minnesota experience. *Am J Clin Oncol* 1996; **19**: 102.
75. Serafini AN, Houston SJ, Resche I et al: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled study. *J Clin Oncol* 1998; **16**: 1574.
76. Sartor O, Reid RH, Hoskin PJ et al: Samarium-153-lexidronam complex for the treatment of painful bone metastases in hormone refractory prostate cancer. *Urology* 2004; **63**: 940.
77. Sartor O, Reid RH, Bushnell DL et al: Safety and efficacy of repeat administration of samarium sm-153 lexidronam to patients with metastatic bone pain. *Cancer* 2007; **109**: 637.
78. Smith DC, Smith MR, Sweeney C et al: Cabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trial. *J Clin Oncol* 2013; **31**: 412.

# American Urological Association

## Castration-Resistant Prostate Cancer

Panel, Consultants, Staff and COI

### Castration-Resistant Prostate Cancer Panel, Consultants and Staff

Michael S. Cookson, MD, Chair  
Vanderbilt University  
Nashville, TN

Adam S. Kibel, MD, Vice Chair  
Harvard Program in Urology (Longwood)  
Boston, MA

Philipp Dahm, MD, MHSc  
University of Florida  
Gainesville, FL

Christine Engstrom, PhD, CRNP, AOCN  
Department of Veterans Affairs  
Washington, DC

Stephen J. Freedland, MD  
Duke University  
Durham, NC

Maha Hussain, MD, FACP  
University of Michigan Comprehensive Cancer Center  
Ann Arbor, MI

Daniel W. Lin, MD  
University of Washington  
Seattle, WA

William T. Lowrance, MD  
Huntsman Cancer Hospital  
Salt Lake City, UT

William K. Oh, MD  
Mount Sinai School of Medicine  
New York, NY

David F. Penson, MD  
Vanderbilt University  
Nashville, TN

Bruce J. Roth, MD  
Washington University in St. Louis School of Medicine  
St. Louis, MO

#### Consultants

Mohammad Hassan Murad, MD, MPH  
Osama Altayar, MD  
Mohammed Nabhan, MD

#### Staff

Heddy Hubbard, PhD., MPH, RN, FAAN  
Michael Folmer  
Abid Khan, MHS  
Carla Foster, MPH  
Erin Kirkby, MS

Patricia Lapera, MPH  
Del'Rhea Godwin-Brent

### CONFLICT OF INTEREST DISCLOSURES

All panel members completed COI disclosures. Relationships that have expired (more than one year old) since the panel's initial meeting, are listed. Those marked with (C) indicate that compensation was received; relationships designated by (U) indicate no compensation was received.

**Consultant/Advisor:** **Michael S. Cookson**, Spectrum (C), Myriad (C), US HIFU(C), Endo (C), GE Healthcare (C), Covidien (C); **Stephen J. Freedland**, Amgen (C), Medivation (C), Bayer (C), Mitomics (C), Astellas (C), AstraZeneca (C), Dendreon (C), Janssen (C), Glaxo Smith Kline (C) (Expired); **Maha Hussain**, Merck (C), Lilly (C), Exelexis (C), Johnson & Johnson (C); **Adam S. Kibel**, Dendreon (C), Myriad Genetics (C), National Cancer Institute (C), Sanofi-Aventis (C), Spectrum (C); **Daniel W. Lin**, Caris Life Sciences (U), Dendreon Corporation (C), GenProbe (U), Myriad Genetics (C), Pfizer (C); **William T. Lowrance**, Myriad Genetics (C), Dendreon (C); **William K. Oh**, Active Biotech (C), Amgen (C), Astellas (C), Bayer (C), Bellicum Pharmaceuticals (C), Centocor Ortho Biotech (C), Dendreon (C), Genentech (U), Imedex (C), Janssen (C), Medivation (C), Millenium (U), Pfizer (C), sanofi-aventis (C)

**Investigator:** **William K. Oh**, Genentech (U) (Expired), Millenium (C) (Expired)

**Meeting Participant or Lecturer:** **Michael S. Cookson**, Photocure (C); **Stephen J. Freedland**, AstraZeneca (C), Dendreon (C), Amgen (C)(Expired), AstraZeneca (C)(Expired), Centocor Ortho Biotech (C) (Expired); **Maha Hussain**, Ferring (C), Astra Zeneca (C); **Adam S. Kibel**, Dendreon (C), Sanofi-Aventis (C) (Expired); **Daniel W. Lin**, Dendreon Corporation (C), Myriad (C); **William K. Oh**, sanofi-aventis (C) (Expired)

**Scientific Study or Trial:** **Michael S. Cookson**, Endo (C), GE Healthcare (C), Covidien (C); **Stephen J. Freedland**, Glaxo Smith Kline (C) (Expired), Dendreon (C) (Expired), Janssen (C); **Maha Hussain**, Imclone (U), celgene (U), Millenium (U), Abbott (U), EMD Serono (U), Genta (U), Abraxis, (U) (Expired); **Adam S. Kibel**, Sanofi-Aventis (C); **Daniel W. Lin**, Department of Defense (C), GenProbe (U), NIH/NCI (C), Sanofi-Aventis (C), Veteran's Affairs (U); **William K. Oh**, Pfizer (C) (Expired); **Bruce J. Roth**, Oncogenix (U), Exelixis (U), Medivation (U)

**Peer Reviewers**

We are grateful to the persons listed below who contributed to the Hematuria Guideline by providing comments during the peer review process. Their reviews do not necessarily imply endorsement of the Guideline.

Andrew J Armstrong, MD  
 Daniel A. Barocas, MD  
 John M. Barry, MD  
 William W. Bohnert, MD  
 Rodney Henry Breau, MD  
 Steven Eric Canfield, MD  
 Daniel J. Culkin, MD  
 Robert Dreicer, MD  
 Christopher Paul Evans, MD  
 Robert J. Hamilton, MD  
 Lauren Harshman, DFCI  
 C. D. Anthony Herndon, MD  
 S. Duke Herrell III, MD  
 Arif Hussain, MD  
 Matthew G. Kaag, MD  
 Sushil S. Lacy, MD  
 Deborah J. Lightner, MD  
 Kevin R. Loughlin, MD  
 Bruce Montgomery, MD  
 Joel Picus, MD  
 Kevin Pranikoff, MD  
 Hassan Razvi, MD  
 Charles Joel Rosser, MD  
 Paul F. Schellhammer, MD  
 Joseph Smith, MD  
 Pramod C. Sogani, MD  
 J. Brantley Thrasher, MD  
 James A. Trovato, PharmD, MBA, BCOP, FASHP  
 John F. Ward, III, MD  
 J. Stuart Wolf, Jr., MD

**DISCLAIMER**

This document was written by the Castration-Resistant Prostate Cancer Guidelines Panel of the American Urological Association Education and Research, Inc., which was created in 2011. The Practice Guidelines Committee (PGC) of the AUA selected the committee chair. Panel members were selected by the chair. Membership of the committee included urologists, and oncologists and other clinicians with specific expertise on this disorder. The mission of the committee was to develop recommendations that are analysis-based or consensus-based, depending on Panel processes and available data, for optimal clinical practices in the treatment of Castration-Resistant Prostate Cancer.

Funding of the committee was provided by the AUA. Committee members received no remuneration for their work. Each member of the committee provides an ongoing conflict of interest disclosure to the AUA.

While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change. Today these evidence-based guidelines statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician judgment in individual cases.

Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome. The guideline text may include information or recommendations about certain drug uses ('off label') that are not approved by the Food and Drug Administration (FDA), or about medications or substances not subject to the FDA approval process. AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings. These guidelines and best practice statements are not in-tended to provide legal advice about use and misuse of these substances.

Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices.

For this reason, the AUA does not regard technologies or management which are too new to be addressed by this guideline as necessarily experimental or investigational.